Treatment Study for Patients with Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin

Clinical Trial Title

Randomized phase II/III trial of radiotherapy with concurrent MEDI4736 (durvalumab) vs. radiotherapy with concurrent cetuximab in patients with locoregionally advanced head and neck cancer with a contraindication to cisplatin.

Clinical Trial Protocol Description:

This randomized phase II/III trial studies how well radiation therapy works with durvalumab or cetuximab in treating patients with head and neck cancer that has spread to a local and/or regional area of the body who cannot take cisplatin. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Immunotherapy with monoclonal antibodies, such as durvalumab or cetuximab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. It is not known if radiation therapy with durvalumab will work better than the usual therapy of radiation therapy with cetuximab in treating patients with head and neck cancer.

Clinical Trial Eligibility Criteria:

In order to participate you must meet the following criteria:

  • Have locoregionally advanced head and neck squamous cell carcinoma (HNSCC).
  • Are at least 18 years of age.
  • For women of childbearing potential: Have a negative serum or urine pregnancy test within 14 days prior to step 1 registration.

This is a partial list of elgibility requirements.

Study Details

Clinical Trial Investigator

Neilayan Sen, MD

Contact Information

Rush Cancer Center Clinical Trials Office